Oxaliplatin-induced damage of cellular DNA.

作者: Jan M. Woynarowski , Sandrine Faivre , Maryanne C.S. Herzig , Brenda Arnett , William G. Chapman

DOI: 10.1124/MOL.58.5.920

关键词:

摘要: Damage to cellular DNA is believed determine the antiproliferative properties of platinum (Pt) drugs. This study characterized damage by oxaliplatin, a diaminocyclohexane Pt drug with clinical antitumor activity. Compared cisplatin, oxaliplatin formed significantly fewer Pt-DNA adducts (e.g., 0.86 6 0.04 versus 1.36 0.01 adducts/10 base pairs/10 mM drug/1 h, respectively, in CEM cells, P , .01). Oxaliplatin was found induce potentially lethal bifunctional lesions, such as interstrand cross-links (ISC) and DNA-protein (DPC) cells. As total adducts, however, produced (P .05) lesions than did cisplatin: 0.7 0.2 1.8 0.3 ISC 0.8 0.1 1.5 DPC/10 drug, after 4-h treatment. Extended postincubation (up 12 h) not compensate lower DPC levels oxaliplatin. determinations isolated nuclei unequivocally verified that inherently less able cisplatin form these lesions. Reactivation drug-treated plasmids, observed four cell lines, suggests are repaired similar kinetics adducts. Oxaliplatin, more efficient per equal number inhibiting chain elongation (;7-fold cells). Despite reactivity, exhibited or greater cytotoxicity several other human tumor lines (50% growth inhibition cells at 1.1/1.2 mM, respectively). The results demonstrate oxaliplatin-induced including DPC, likely contribute drug’s biological properties. However, requires does achieve inhibition.

参考文章(41)
J. J. Roberts, R. J. Knox, M. F. Pera, F. Friedlos, D. A. Lydall, The Role of Platinum-DNA Interactions in the Cellular Toxicity and Anti-Tumour Effects of Platinum Co-Ordination Compounds Springer, Boston, MA. pp. 16- 31 ,(1988) , 10.1007/978-1-4613-1717-3_2
Wyrick Sd, Chaney Sg, Luo Fr, Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells. Oncology Research. ,vol. 10, pp. 595- 603 ,(1998)
Raymond B. Weiss, Michaele C. Christian, New cisplatin analogues in development. A review. Drugs. ,vol. 46, pp. 360- 377 ,(1993) , 10.2165/00003495-199346030-00003
Carol L. MacLeod, Sibylle Nebel, Randolph D. Christen, Paula S. Norris, Tzu-Ping Lin, Stefan Aebi, Stephen B. Howell, Martin Haas, Hua Zheng, Alissar Nehmé, Daniel Fink, In Vitro and in Vivo Resistance to Cisplatin in Cells That Have Lost DNA Mismatch Repair Cancer Research. ,vol. 57, pp. 1841- 1845 ,(1997)
Edward L. Mamenta, William K. Kaufmann, Stephen G. Chaney, Dean A. Delmastro, Heather L. Grady, Eric E. Poma, Enhanced Replicative Bypass of Platinum-DNA Adducts in Cisplatin-resistant Human Ovarian Carcinoma Cell Lines Cancer Research. ,vol. 54, pp. 3500- 3505 ,(1994)
Stephen G. Chaney, Wendelyn Schmidt, Role of carrier ligand in platinum resistance of human carcinoma cell lines. Cancer Research. ,vol. 53, pp. 799- 805 ,(1993)
Eric D. Scheeff, James M. Briggs, Stephen B. Howell, Molecular Modeling of the Intrastrand Guanine-Guanine DNA Adducts Produced by Cisplatin and Oxaliplatin Molecular Pharmacology. ,vol. 56, pp. 633- 643 ,(1999) , 10.1124/MOL.56.3.633
Sibylle Nebel, Randolph D. Christen, Stefan Aebi, Stephen B. Howell, Hua Zheng, Bruno Cenni, Alissar Nehmé, Daniel Fink, The role of DNA mismatch repair in platinum drug resistance. Cancer Research. ,vol. 56, pp. 4881- 4886 ,(1996)
Katherine V Ferry, Daniel Fink, Steven W Johnson, Sibylle Nebel, Thomas C Hamilton, Stephen B Howell, Decreased cisplatin damage-dependent DNA synthesis in cellular extracts of mismatch repair deficient cells Biochemical Pharmacology. ,vol. 57, pp. 861- 867 ,(1999) , 10.1016/S0006-2952(98)00366-9